Summary Epidermal growth factor and transforming growth factor alpha are two peptides which bind to the epidermal growth factor receptor. One hundred and seventy-four samples from 133 patients with ovarian cancer were examined for EGF and TGFa. EGF was detected in only 27.6% of samples while TGFa was present in 88.5%. The median values for TGFa presence were at least 10-fold greater than those of EGF. There was no statistical difference between either TGFa or EGF levels and degree of differentiation of the tumours. There was no statistical difference between stage three and four in relation to concentration of either peptide. Median concentration did not differ significantly among the histological sub-groups.
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Epidermal growth factor (EGF) interacts with its receptor, epidermal growth factor receptor (EGFR), initiating the responses which can lead to growth modulation. Additionally such ligand-receptor interaction induces pleiotropic effects in the cell including enhanced glycolysis, increased amino acid transport, calcium, sodium and hydrogen ion exchange and protein synthesis (Owen et al., 1982) . Another growth factor, transforming growth factor alpha (TGFa) binds to the EGFR. Sporn and Roberts (1985) Tumour extract (250 ilI) was added in duplicate to eppendorfs. The primary antibody (either anti EGF or TGFa) was added to each eppendorf in a volume of 250 lAl. Finally 250 il of I12' EGF was added to the eppendorfs in which the primary antibody was anti EGF and 1125 TGFa when the antibody was anti TGFa. The eppendorfs were capped, gently vortexed and incubated at 4°C for 48 h. The standards were treated in the same way.
Secondary antibody (donkey/antisheep -Scottish antibody production unit) at a dilution of 1: 15 (made up in RIA buffer) in a volume of 250 LI was added to unknowns and standards. Incubation continued for a further 24 h at 4°C.
All specimens were centrifuged at 40,000 g in a refrigerated centrifuge (Sarstedt) for 20 min. The supernatant was removed with a pasteur attached to a water pump and the pellet remaining was counted on a Thorn EMI 620 Turbo multichannel gamma counter (60% efficiency). The peptide content was read off the standard curve. (Serov et al., 1973) . These were all common epithelial tumours which comprised serous, endometrioid, mucinous, clear cell and undifferentiated subtypes. All patients were staged in accordance with the revised FIGO staging for ovarian cancer (Shepherd, 1989 
Discussion
TGFa was present in 88.5% of samples compared to EGF which was present in only 27.6% of samples. The range of TGFa overall is vast but the majority of values lie below 5 ng mg-' DNA. EGF was rarely present above 0.3 ng mg-' DNA and there was a 10-fold difference at least between the median values of TGFa compared to EGF. We could find no statistical difference between degree of differentiation of the tumour and TGFa or EGF values. Concentration of TGFa or EGF, in relation to patient follow-up will be assessed at a later date. Kohler et al. (1989) looked at EGF-like factors in ovarian and cervical cancers. They found that 30% of tumour extracts contained higher EGF-like factors (EGF-F 4-15 ng mg-') than those found in non-malignant specimens. They also found that in ovarian carcinoma patients with high EGF-F levels had a poor prognosis. Arteaga et al. (1988) found that 42% of ovarian cancers contained immunoreactive TGFa activity. They also state that this TGFx correlated with patient performance status (PS) and tumour burden. Bauknecht et al. (1986) Hanauske et al. (1988) looked at TGFa in effusions from cancer patients using a rat TGFa raised in sheep against the C-terminal 17 amino acids. The lower limit of detection was only 1.56 ng ml-'. They found TGFx activity more frequently in effusions from cancer patients than controls. Others have found TGFa-like substances in the urine of cancer patients. However, the assays for TGFa were not specific and would have detected other EGF-related growth factors (Twardzik et al., 1982; Sherwin et al., 1983; Kimball et al., 1984) . TGFa is found in effusions even in the absence of positive cytology. We also found TGFa in ascitic fluid (Owens, MD thesis, 1990) with positive cytology and also in fluid where tumour cells were absent (benign cysts and free fluid). Arteaga et al. (1988) and Stromberg et al. (1987) suggest that TGFa levels in the serous effusions from cancer patients are a reliable index for tumour burden and overall patient survival. It is interesting that Hanauske et al. (1988) state that the TGFa activity is not characteristic of any single tumour type as they were unable to detect any difference between breast, ovary and lung primaries.
In conclusion TGFa was present in a greater proportion of patients and also in larger quantities compared to EGF. Neither peptide appears to show any significant difference in levels with regard to stage, differentiation or type of tumour. It is hoped that when follow-up is sufficiently long that we may be able to compare TGFa and EGF with survival and death. (British Medical Association) . We wish to thank ICI for their gift of peptides (EGF and TGFx) and also their antibodies to these peptides. Tumour specimens were gratefully received from gynaecologists and pathologists in the West of Scotland. We wish to thank Janet Findlay and Audrey Laurence for statistical advice and Jean McDonald for assistance in illustrating the graphs presented in this paper.
